Results 71 to 80 of about 1,010,901 (298)

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Prediction of biochemical recurrence after laparoscopic radical prostatectomy

BMC Urology, 2023
Background Radical prostatectomy (RP) has been considered primary treatment for localized prostate cancer. Biochemical recurrence (BCR) occur approximately 20–30% in five year after RP.
Tanan Bejrananda, Pitchaya Pliensiri
doaj   +1 more source

Biochemical Recurrence After Radiation Therapy

, 2018
Our patient was considered intermediate risk status prior to his original treatment. At this point he has experienced a biochemical failure and has a very strong potential for disease recurrence. With a PSA of 4.5, metastasis is less likely, but imaging modalities are not adequately sensitive to eliminate the possibility of metastatic foci.
Christopher Martin, William Lowrance
openaire   +1 more source

Apatinib in treating clinical and biochemical recurrent ovarian cancer [PDF]

, 2019
Abstract Background: Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), exerts antiangiogenic effects. Taken orally, apatinib shows clinical activity in the treatment of recurrent or platinum-resistant ovarian cancer (OC) as monotherapy or in combination with other chemotherapeutic agents.
Zhongyu Wang, Yake Huang, Ling Long, Li Zhou, Yan Huang, Lei Gan, Aimin Pu, Sufen Li, Rongkai Xie   +8 more
openaire   +2 more sources

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Salvage conformal radiotherapy for biochemical recurrent prostate cancer after radical prostatectomy

International Brazilian Journal of Urology, 2006
OBJECTIVE: Assess the results of salvage conformal radiotherapy in patients with biochemical failure after radical prostatectomy and identify prognostic factors for biochemical recurrence and toxicity of the treatment.
Carlos R. Monti, Ricardo A. Nakamura, Robson Ferrigno, Aristides Rossi Jr, Neusa S. Kawakami, Felipe A. Trevisan   +5 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Surgical treatment of local recurrence after radical prostatectomy: Robot-assisted surgical approach combined with three-dimensional virtual reconstruction

Urology Case Reports
The treatment of local recurrence after radical prostatectomy and salvage pelvic irradiation, has no consensus in the literature. A surgical approach is possible, the main benefit of which is delaying an androgen blockade.We present a patient who evolved
Matheus N.M. Reis, Bruno H.O.S. Lopes, Paulo B.O. Arantes, Stella D.S. Ramos, Pedro R. de Castro   +4 more
doaj   +1 more source

Biochemical recurrence‐free conditional probability after radical prostatectomy: A dynamic prognosis [PDF]

, 2019
Objective To estimate the conditional biochemical recurrence-free probability and to develop a predictive model according to the disease-free interval for men with clinically localized prostate cancer treated with minimally invasive radical prostatectomy.
Fabio Muttin, Sanchez-Salas, R., Igor Nunes‐Silva, Muttin, F., Silvia García‐Barreras, Garcia-Barreras, S., Carlos Mejia‐Monasterio, Mejia-Monasterio, C., Rafael Sanchez‐Salas, Dell'Oglio, P., François Rozet, Paolo Dell'Oglio, Secin, F., Victor Srougi, Cathelineau, X., Srougi, V., Fernando Secin, Nunes-Silva, I., Barret, E., Eric Barret, Xavier Cathelineau, Dominique Prapotnich, Prapotnich, D., Rozet, F.   +23 more
core   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source